In a move that underscores the strategic significance of regulatory exclusivity in the pharmaceutical industry, the FDA has granted Phathom Pharmaceuticals a full 10-year exclusivity for their drug Voquezna. This remarkable decision was triggered by a citizen petition asserting that Voquezna, embodying the active moiety vonoprazan, similarly found in the previously approved Voquezna Triple Pak […]